Business, energy, technology, markets and global industry news from Business News Today

ZUSDURI

PharmaDeviceNews ZUSDURI
UroGen Pharma’s investment of up to $7 million in IntraGel, alongside an option on TumoCure and potential rights to three additional SRGel oncology programmes, expands its interest in localized drug-delivery technology for cancer treatment. Representative image.
Pharma & Biotech

Why UroGen Pharma is looking beyond bladder cancer with IntraGel’s cisplatin-loaded SRGel platform

UroGen Pharma will invest up to $7 million in IntraGel while securing an option on TumoCure and potential rights to three additional SRGel oncology programmes.

Read More
Pharma & Biotech

Why UroGen Pharma Ltd. sees UGN-103 as more than a follow-on bladder cancer therapy

UroGen Pharma Ltd.’s UGN-103 posted strong Phase 3 bladder cancer durability data. Find out what this means for NMIBC treatment and regulation.

Read More